|
ZNF493 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.09854356114647E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.31879951403846E-10 |
| Normal-vs-Stage2 |
2.34149999999156E-05 |
| Normal-vs-Stage3 |
9.99200722162641E-16 |
| Normal-vs-Stage4 |
1.63269398001376E-12 |
| Stage1-vs-Stage2 |
8.483200E-01 |
| Stage1-vs-Stage3 |
2.962700E-03 |
| Stage1-vs-Stage4 |
5.192100E-04 |
| Stage2-vs-Stage3 |
6.741600E-02 |
| Stage2-vs-Stage4 |
2.015800E-02 |
| Stage3-vs-Stage4 |
3.940400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.44249065417534E-15 |
| Normal-vs-AfricanAmerican |
7.76809999658568E-08 |
| Normal-vs-Asian |
3.74510000000772E-06 |
| Caucasian-vs-AfricanAmerican |
7.425600E-01 |
| Caucasian-vs-Asian |
9.385600E-02 |
| AfricanAmerican-vs-Asian |
1.875250E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.93000060377813E-11 |
| Normal-vs-Female |
5.22193399632442E-12 |
| Male-vs-Female |
7.861600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.16220000290213E-09 |
| Normal-vs-Age(41-60Yrs) |
7.42517158869305E-13 |
| Normal-vs-Age(61-80Yrs) |
2.05080397108759E-12 |
| Normal-vs-Age(81-100Yrs) |
2.835300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.384300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.850300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.958200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.429600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.417600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.170600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.054340E-02 |
| Classical-VS-Follicular |
7.174000E-01 |
| Classical-VS-Other |
7.636200E-01 |
| Classical-VS-Normal |
7.39985850373159E-12 |
| Tall-VS-Follicular |
2.370500E-02 |
| Tall-VS-Other |
3.673000E-01 |
| Tall-VS-Normal |
5.92820237343972E-11 |
| Follicular-VS-Other |
7.252400E-01 |
| Follicular-VS-Normal |
1.97770000043285E-07 |
| Other-VS-Normal |
1.661020E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.70470304539094E-11 |
| Normal-vs-N1 |
2.10460000538149E-08 |
| N0-vs-N1 |
7.702800E-01 |
|
|
